We have located links that may give you full text access.
The effect of micro-particle curcumin on chronic kidney disease progression: the MPAC-CKD randomized clinical trial.
Nephrology, Dialysis, Transplantation 2023 Februrary 28
BACKGROUND: Curcumin is a commonly used herbal supplement with anti-inflammatory and anti-fibrotic properties. Animal studies and small human trials suggest curcumin reduces albuminuria in patients with chronic kidney disease. Micro-particle curcumin is a new, more bioavailable formulation of curcumin.
METHODS: To determine whether micro-particle curcumin versus placebo slows the progression of albuminuric chronic kidney disease we conducted a randomized, double-blind, placebo-controlled trial with 6-month follow-up. We included adults with albuminuria (a random urine albumin-to-creatinine ratio >30 mg/mmol [265 mg/g] or a 24-hour urine collection with more than 300 mg of protein) and an estimated glomerular filtration rate (eGFR) between 15 and 60 ml/min per 1.73 m2 within the 3 months before randomization. We randomly allocated participants 1:1 to receive micro-particle curcumin capsules (90 mg/day) or matching placebo for 6 months. After randomization. The co-primary outcomes were the changes in albuminuria and the eGFR.
RESULTS: We enrolled 533 participants, but 4/265 participants in the curcumin group and 15/268 in the placebo group withdrew consent or became ineligible. The 6-month change in albuminuria did not differ significantly between the curcumin and placebo groups (geometric mean ratio 0.94, 97.5% confidence interval [CI]: 0.82 to 1.08, P = .32). Similarly, the 6-month change in eGFR did not differ between groups (mean between-group difference -0.22 mL/min per 1.73m2, 97.5% CI: -1.38 to 0.95, P = 0.68).
CONCLUSIONS: Ninety milligrams of micro-particle curcumin daily did not slow the progression of albuminuric chronic kidney disease over six months. Trial Registration: ClinicalTrials.gov Identifier: NCT02369549.
METHODS: To determine whether micro-particle curcumin versus placebo slows the progression of albuminuric chronic kidney disease we conducted a randomized, double-blind, placebo-controlled trial with 6-month follow-up. We included adults with albuminuria (a random urine albumin-to-creatinine ratio >30 mg/mmol [265 mg/g] or a 24-hour urine collection with more than 300 mg of protein) and an estimated glomerular filtration rate (eGFR) between 15 and 60 ml/min per 1.73 m2 within the 3 months before randomization. We randomly allocated participants 1:1 to receive micro-particle curcumin capsules (90 mg/day) or matching placebo for 6 months. After randomization. The co-primary outcomes were the changes in albuminuria and the eGFR.
RESULTS: We enrolled 533 participants, but 4/265 participants in the curcumin group and 15/268 in the placebo group withdrew consent or became ineligible. The 6-month change in albuminuria did not differ significantly between the curcumin and placebo groups (geometric mean ratio 0.94, 97.5% confidence interval [CI]: 0.82 to 1.08, P = .32). Similarly, the 6-month change in eGFR did not differ between groups (mean between-group difference -0.22 mL/min per 1.73m2, 97.5% CI: -1.38 to 0.95, P = 0.68).
CONCLUSIONS: Ninety milligrams of micro-particle curcumin daily did not slow the progression of albuminuric chronic kidney disease over six months. Trial Registration: ClinicalTrials.gov Identifier: NCT02369549.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app